| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gold | 31 | 2020 | 137 | 8.260 |
Why?
|
| Metal Nanoparticles | 27 | 2020 | 137 | 8.130 |
Why?
|
| Ovarian Neoplasms | 21 | 2020 | 607 | 4.500 |
Why?
|
| Nanoparticles | 11 | 2021 | 291 | 3.250 |
Why?
|
| Pancreatic Neoplasms | 13 | 2021 | 548 | 2.860 |
Why?
|
| Antineoplastic Agents | 16 | 2021 | 686 | 2.490 |
Why?
|
| Cystathionine beta-Synthase | 6 | 2020 | 31 | 2.320 |
Why?
|
| Tumor Microenvironment | 6 | 2021 | 194 | 2.250 |
Why?
|
| Nanoconjugates | 6 | 2020 | 18 | 2.230 |
Why?
|
| Cell Line, Tumor | 36 | 2021 | 1350 | 2.220 |
Why?
|
| Nanotechnology | 8 | 2020 | 68 | 1.920 |
Why?
|
| Drug Delivery Systems | 10 | 2021 | 236 | 1.890 |
Why?
|
| Nanomedicine | 7 | 2019 | 62 | 1.800 |
Why?
|
| Mitochondria | 7 | 2020 | 408 | 1.680 |
Why?
|
| Cation Transport Proteins | 3 | 2020 | 60 | 1.520 |
Why?
|
| Neoplasm Proteins | 4 | 2019 | 123 | 1.460 |
Why?
|
| Antibodies, Monoclonal | 5 | 2011 | 336 | 1.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2020 | 472 | 1.200 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 170 | 1.160 |
Why?
|
| Humans | 61 | 2021 | 28851 | 1.150 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 3 | 2020 | 23 | 1.090 |
Why?
|
| Calcium-Binding Proteins | 3 | 2020 | 62 | 1.080 |
Why?
|
| Neovascularization, Pathologic | 6 | 2019 | 148 | 1.030 |
Why?
|
| Cell Proliferation | 20 | 2021 | 824 | 1.010 |
Why?
|
| Polycomb Repressive Complex 1 | 9 | 2018 | 34 | 0.980 |
Why?
|
| Drug Carriers | 5 | 2020 | 119 | 0.910 |
Why?
|
| Animals | 33 | 2021 | 10684 | 0.880 |
Why?
|
| MicroRNAs | 3 | 2020 | 302 | 0.830 |
Why?
|
| Pinocytosis | 2 | 2021 | 17 | 0.830 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2021 | 179 | 0.810 |
Why?
|
| Mice, Nude | 12 | 2021 | 332 | 0.780 |
Why?
|
| Hydrogen Sulfide | 3 | 2020 | 33 | 0.780 |
Why?
|
| Oxidative Stress | 4 | 2020 | 677 | 0.760 |
Why?
|
| Cisplatin | 5 | 2017 | 186 | 0.730 |
Why?
|
| Phototherapy | 2 | 2021 | 28 | 0.720 |
Why?
|
| Gene Silencing | 4 | 2020 | 65 | 0.710 |
Why?
|
| Clathrin | 1 | 2021 | 20 | 0.710 |
Why?
|
| Signal Transduction | 9 | 2020 | 1469 | 0.710 |
Why?
|
| Glycolysis | 3 | 2020 | 96 | 0.700 |
Why?
|
| Neoplasms | 4 | 2011 | 874 | 0.690 |
Why?
|
| Endothelium, Vascular | 4 | 2020 | 334 | 0.680 |
Why?
|
| Mitochondrial Dynamics | 1 | 2020 | 18 | 0.650 |
Why?
|
| Mice | 21 | 2021 | 4802 | 0.650 |
Why?
|
| Protein Corona | 1 | 2020 | 9 | 0.640 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 62 | 0.640 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2017 | 140 | 0.620 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2019 | 10 | 0.610 |
Why?
|
| Female | 26 | 2021 | 15624 | 0.600 |
Why?
|
| Tissue Distribution | 3 | 2014 | 137 | 0.590 |
Why?
|
| Carrier Proteins | 1 | 2020 | 255 | 0.580 |
Why?
|
| ErbB Receptors | 5 | 2011 | 100 | 0.580 |
Why?
|
| Apoptosis | 11 | 2018 | 780 | 0.570 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2011 | 108 | 0.540 |
Why?
|
| Mitochondrial Proteins | 1 | 2018 | 80 | 0.540 |
Why?
|
| Platinum | 3 | 2012 | 18 | 0.520 |
Why?
|
| Silver | 3 | 2012 | 21 | 0.520 |
Why?
|
| Endocytosis | 4 | 2021 | 96 | 0.520 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 95 | 0.510 |
Why?
|
| Cetuximab | 6 | 2020 | 22 | 0.510 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2016 | 120 | 0.510 |
Why?
|
| Pharmaceutical Preparations | 2 | 2014 | 48 | 0.500 |
Why?
|
| Lipogenesis | 1 | 2015 | 29 | 0.470 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2016 | 67 | 0.470 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 5 | 2021 | 56 | 0.470 |
Why?
|
| Triglycerides | 1 | 2015 | 123 | 0.460 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 146 | 0.440 |
Why?
|
| Microscopy, Electron, Transmission | 6 | 2013 | 82 | 0.440 |
Why?
|
| Particle Size | 6 | 2021 | 105 | 0.430 |
Why?
|
| Cell Movement | 8 | 2019 | 376 | 0.420 |
Why?
|
| Cholesterol | 1 | 2015 | 203 | 0.420 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2011 | 29 | 0.400 |
Why?
|
| Designer Drugs | 1 | 2013 | 2 | 0.400 |
Why?
|
| Deoxycytidine | 4 | 2020 | 67 | 0.390 |
Why?
|
| Proteins | 2 | 2020 | 254 | 0.380 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 164 | 0.380 |
Why?
|
| Nuclear Proteins | 3 | 2016 | 249 | 0.370 |
Why?
|
| Repressor Proteins | 2 | 2011 | 119 | 0.370 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2012 | 24 | 0.370 |
Why?
|
| Adenocarcinoma | 3 | 2013 | 300 | 0.360 |
Why?
|
| Calcium | 5 | 2017 | 243 | 0.350 |
Why?
|
| Drug Design | 1 | 2011 | 63 | 0.350 |
Why?
|
| Surface Properties | 4 | 2014 | 134 | 0.350 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2018 | 275 | 0.340 |
Why?
|
| Biological Transport | 3 | 2021 | 128 | 0.330 |
Why?
|
| Materials Testing | 2 | 2021 | 89 | 0.320 |
Why?
|
| Disease | 2 | 2020 | 15 | 0.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2011 | 151 | 0.320 |
Why?
|
| Phenotype | 4 | 2017 | 685 | 0.320 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 465 | 0.310 |
Why?
|
| Cell Membrane | 2 | 2010 | 268 | 0.300 |
Why?
|
| Veratrum Alkaloids | 1 | 2008 | 4 | 0.300 |
Why?
|
| Pancreatic Stellate Cells | 2 | 2020 | 6 | 0.290 |
Why?
|
| Hedgehog Proteins | 1 | 2008 | 35 | 0.290 |
Why?
|
| Cell Line | 5 | 2018 | 700 | 0.280 |
Why?
|
| Tumor Cells, Cultured | 3 | 2019 | 314 | 0.280 |
Why?
|
| Transfection | 4 | 2015 | 319 | 0.270 |
Why?
|
| Nanostructures | 1 | 2008 | 64 | 0.270 |
Why?
|
| Cells, Cultured | 6 | 2020 | 1022 | 0.270 |
Why?
|
| Endoplasmic Reticulum | 2 | 2020 | 80 | 0.260 |
Why?
|
| Disease Models, Animal | 5 | 2018 | 1507 | 0.260 |
Why?
|
| Gene Knockdown Techniques | 4 | 2016 | 134 | 0.250 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 404 | 0.240 |
Why?
|
| Cell Survival | 4 | 2021 | 419 | 0.240 |
Why?
|
| Down-Regulation | 2 | 2018 | 202 | 0.240 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 198 | 0.240 |
Why?
|
| Models, Biological | 5 | 2020 | 469 | 0.230 |
Why?
|
| Light | 2 | 2014 | 118 | 0.200 |
Why?
|
| Microscopy, Confocal | 3 | 2013 | 113 | 0.190 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 59 | 0.190 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 415 | 0.190 |
Why?
|
| Heterografts | 3 | 2018 | 66 | 0.180 |
Why?
|
| Static Electricity | 2 | 2013 | 35 | 0.180 |
Why?
|
| Blotting, Western | 4 | 2013 | 515 | 0.180 |
Why?
|
| Gene Expression | 2 | 2013 | 417 | 0.180 |
Why?
|
| Ultraviolet Rays | 1 | 2021 | 40 | 0.180 |
Why?
|
| Reactive Oxygen Species | 3 | 2018 | 292 | 0.170 |
Why?
|
| Physiological Phenomena | 1 | 2020 | 2 | 0.170 |
Why?
|
| Photoacoustic Techniques | 1 | 2021 | 17 | 0.170 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2020 | 14 | 0.170 |
Why?
|
| Kinetics | 2 | 2020 | 553 | 0.170 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2020 | 6 | 0.170 |
Why?
|
| Skin | 1 | 2021 | 152 | 0.170 |
Why?
|
| Lysophospholipids | 2 | 2018 | 51 | 0.170 |
Why?
|
| Endothelial Cells | 2 | 2019 | 373 | 0.160 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 48 | 0.160 |
Why?
|
| Protein Domains | 1 | 2020 | 53 | 0.160 |
Why?
|
| Enzyme Activation | 1 | 2020 | 267 | 0.160 |
Why?
|
| Cystathionine gamma-Lyase | 1 | 2019 | 7 | 0.160 |
Why?
|
| Protein Binding | 5 | 2017 | 667 | 0.160 |
Why?
|
| Sulfurtransferases | 1 | 2019 | 11 | 0.160 |
Why?
|
| Immunomodulation | 1 | 2019 | 20 | 0.150 |
Why?
|
| Autophagy | 2 | 2020 | 77 | 0.150 |
Why?
|
| Sepsis | 1 | 2020 | 86 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2020 | 82 | 0.150 |
Why?
|
| Liposomes | 1 | 2020 | 145 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 103 | 0.150 |
Why?
|
| Peptides | 1 | 2021 | 296 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 101 | 0.150 |
Why?
|
| DNA Damage | 1 | 2019 | 152 | 0.140 |
Why?
|
| Phosphorylation | 4 | 2019 | 585 | 0.140 |
Why?
|
| Dynamin II | 2 | 2010 | 13 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 105 | 0.140 |
Why?
|
| Pyrazines | 1 | 2017 | 25 | 0.140 |
Why?
|
| Benzimidazoles | 1 | 2017 | 32 | 0.140 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2017 | 19 | 0.130 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 29 | 0.130 |
Why?
|
| Tumor Burden | 2 | 2016 | 110 | 0.130 |
Why?
|
| Microarray Analysis | 1 | 2017 | 65 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 285 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 2 | 2015 | 124 | 0.130 |
Why?
|
| Adenosine Triphosphate | 2 | 2016 | 121 | 0.130 |
Why?
|
| Carbocyanines | 2 | 2021 | 10 | 0.130 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 480 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 189 | 0.130 |
Why?
|
| Histone Acetyltransferases | 1 | 2016 | 15 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 1 | 2016 | 20 | 0.120 |
Why?
|
| Silicon Dioxide | 2 | 2021 | 43 | 0.120 |
Why?
|
| Male | 5 | 2014 | 13921 | 0.120 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2015 | 4 | 0.120 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2015 | 17 | 0.120 |
Why?
|
| Sp1 Transcription Factor | 1 | 2015 | 17 | 0.120 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 33 | 0.120 |
Why?
|
| Homeostasis | 1 | 2016 | 119 | 0.120 |
Why?
|
| RNA Interference | 1 | 2015 | 137 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 163 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 190 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 94 | 0.110 |
Why?
|
| Cytoprotection | 1 | 2014 | 24 | 0.110 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2011 | 54 | 0.110 |
Why?
|
| Half-Life | 1 | 2014 | 34 | 0.110 |
Why?
|
| Genotype | 1 | 2015 | 461 | 0.110 |
Why?
|
| Drug Synergism | 1 | 2014 | 106 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2014 | 95 | 0.110 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 209 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2016 | 427 | 0.100 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2013 | 30 | 0.100 |
Why?
|
| Neoplasms, Experimental | 2 | 2021 | 58 | 0.100 |
Why?
|
| Cadherins | 1 | 2013 | 24 | 0.100 |
Why?
|
| Docosahexaenoic Acids | 1 | 2014 | 109 | 0.100 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 10 | 0.100 |
Why?
|
| Vimentin | 1 | 2013 | 28 | 0.100 |
Why?
|
| Body Fluids | 1 | 2013 | 18 | 0.100 |
Why?
|
| Scattering, Radiation | 1 | 2013 | 29 | 0.100 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2014 | 131 | 0.100 |
Why?
|
| Mutation | 3 | 2017 | 867 | 0.100 |
Why?
|
| Computational Biology | 1 | 2014 | 156 | 0.100 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2013 | 39 | 0.100 |
Why?
|
| Necrosis | 2 | 2016 | 85 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2065 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 133 | 0.100 |
Why?
|
| Models, Molecular | 1 | 2014 | 452 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 612 | 0.100 |
Why?
|
| Endosomes | 2 | 2010 | 53 | 0.100 |
Why?
|
| Proteomics | 1 | 2014 | 197 | 0.090 |
Why?
|
| Antimalarials | 1 | 2012 | 25 | 0.090 |
Why?
|
| Antibodies, Immobilized | 1 | 2011 | 4 | 0.090 |
Why?
|
| Disease Progression | 1 | 2013 | 477 | 0.090 |
Why?
|
| Antioxidants | 1 | 2013 | 224 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 137 | 0.090 |
Why?
|
| Folate Receptor 1 | 1 | 2011 | 13 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2009 | 48 | 0.090 |
Why?
|
| Molecular Structure | 1 | 2012 | 245 | 0.090 |
Why?
|
| Ligands | 1 | 2011 | 178 | 0.090 |
Why?
|
| Prognosis | 3 | 2020 | 811 | 0.090 |
Why?
|
| Carboplatin | 1 | 2011 | 121 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 328 | 0.080 |
Why?
|
| Golgi Apparatus | 1 | 2010 | 26 | 0.080 |
Why?
|
| Membrane Potentials | 1 | 2010 | 65 | 0.080 |
Why?
|
| Protein Conformation | 1 | 2011 | 258 | 0.080 |
Why?
|
| Lysosomes | 1 | 2010 | 56 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 18 | 0.080 |
Why?
|
| 3' Untranslated Regions | 1 | 2009 | 34 | 0.080 |
Why?
|
| Surface Plasmon Resonance | 1 | 2009 | 37 | 0.080 |
Why?
|
| Sonication | 1 | 2009 | 1 | 0.080 |
Why?
|
| Time Factors | 2 | 2011 | 1613 | 0.080 |
Why?
|
| Nitric Oxide | 1 | 2010 | 153 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2013 | 523 | 0.080 |
Why?
|
| Serum Albumin, Bovine | 1 | 2009 | 22 | 0.080 |
Why?
|
| Salts | 1 | 2008 | 12 | 0.070 |
Why?
|
| Umbilical Veins | 2 | 2005 | 25 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2009 | 79 | 0.070 |
Why?
|
| Radio Waves | 1 | 2008 | 21 | 0.070 |
Why?
|
| Terbium | 1 | 2007 | 2 | 0.070 |
Why?
|
| Europium | 1 | 2007 | 3 | 0.070 |
Why?
|
| Aged | 2 | 2018 | 5598 | 0.070 |
Why?
|
| Histones | 2 | 2019 | 96 | 0.070 |
Why?
|
| Nanotubes | 1 | 2007 | 15 | 0.070 |
Why?
|
| Phosphates | 1 | 2007 | 33 | 0.070 |
Why?
|
| Hyperthermia, Induced | 1 | 2008 | 30 | 0.070 |
Why?
|
| Caspases | 2 | 2018 | 43 | 0.070 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 93 | 0.070 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 380 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2013 | 2426 | 0.060 |
Why?
|
| Middle Aged | 2 | 2018 | 7414 | 0.060 |
Why?
|
| Young Adult | 1 | 2013 | 2833 | 0.060 |
Why?
|
| Adult | 2 | 2018 | 8024 | 0.060 |
Why?
|
| Intracellular Space | 1 | 2005 | 12 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2005 | 44 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 90 | 0.060 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 74 | 0.060 |
Why?
|
| Trans-Activators | 1 | 2005 | 118 | 0.060 |
Why?
|
| Risk Factors | 2 | 2020 | 2126 | 0.050 |
Why?
|
| Glutathione | 2 | 2015 | 76 | 0.050 |
Why?
|
| Mice, Hairless | 1 | 2021 | 1 | 0.050 |
Why?
|
| Sunburn | 1 | 2021 | 2 | 0.050 |
Why?
|
| Indocyanine Green | 1 | 2021 | 16 | 0.050 |
Why?
|
| Ferric Compounds | 1 | 2021 | 43 | 0.040 |
Why?
|
| Cell Nucleus | 2 | 2016 | 138 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 96 | 0.040 |
Why?
|
| Histone Deacetylase 1 | 1 | 2019 | 10 | 0.040 |
Why?
|
| Histone Deacetylase 2 | 1 | 2019 | 10 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2021 | 163 | 0.040 |
Why?
|
| Editorial Policies | 1 | 2019 | 7 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 90 | 0.040 |
Why?
|
| Zebrafish | 1 | 2020 | 96 | 0.040 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2020 | 178 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 53 | 0.040 |
Why?
|
| Research | 1 | 2019 | 93 | 0.040 |
Why?
|
| Hexokinase | 1 | 2018 | 16 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2018 | 21 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2018 | 35 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2018 | 69 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2017 | 5 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 87 | 0.030 |
Why?
|
| Casein Kinase II | 1 | 2017 | 17 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2016 | 12 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 59 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 787 | 0.030 |
Why?
|
| Lysine Acetyltransferase 5 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 41 | 0.030 |
Why?
|
| Alarmins | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 23 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 22 | 0.030 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2016 | 3 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2016 | 77 | 0.030 |
Why?
|
| Neuropilins | 1 | 2015 | 4 | 0.030 |
Why?
|
| Second Messenger Systems | 1 | 2015 | 13 | 0.030 |
Why?
|
| Thiazoles | 1 | 2016 | 50 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2016 | 200 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 141 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2015 | 65 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 432 | 0.030 |
Why?
|
| Retinaldehyde | 1 | 2014 | 7 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 344 | 0.030 |
Why?
|
| Diterpenes | 1 | 2014 | 19 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 265 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2016 | 874 | 0.030 |
Why?
|
| S-Nitroso-N-Acetylpenicillamine | 1 | 2010 | 6 | 0.020 |
Why?
|
| Nitric Oxide Donors | 1 | 2010 | 11 | 0.020 |
Why?
|
| Hepatic Stellate Cells | 1 | 2010 | 23 | 0.020 |
Why?
|
| Diffusion | 1 | 2009 | 39 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2009 | 32 | 0.020 |
Why?
|
| Microspheres | 1 | 2009 | 49 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 222 | 0.020 |
Why?
|
| Immunoconjugates | 1 | 2008 | 21 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2007 | 98 | 0.020 |
Why?
|
| Rats | 1 | 2009 | 1588 | 0.010 |
Why?
|
| GTP Phosphohydrolases | 1 | 2005 | 19 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 2005 | 29 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 29 | 0.010 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2005 | 14 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2005 | 26 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 68 | 0.010 |
Why?
|
| Cell Separation | 1 | 2005 | 57 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 2005 | 34 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2005 | 68 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 101 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2005 | 43 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2005 | 163 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 163 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 128 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 292 | 0.010 |
Why?
|
| Thrombosis | 1 | 2005 | 150 | 0.010 |
Why?
|
| Cytokines | 1 | 2005 | 451 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 485 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 667 | 0.010 |
Why?
|